Sulfinpyrazone

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Sulfinpyrazone
Sulfinpyrazone.svg
Clinical data
Trade namesApo-sulfinpyrazone
AHFS/Drugs.comMonograph
MedlinePlusa682339
Routes of
administration
oral intravenous
ATC code
Pharmacokinetic data
Protein binding98–99%
Metabolismhepatic
Excretionrenal
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard100.000.325 Edit this at Wikidata
Chemical and physical data
FormulaC23H20N2O3S
Molar mass404.48 g/mol
3D model (JSmol)
  (verify)

Sulfinpyrazone is a uricosuric medication used to treat gout. It also sometimes is used to reduce platelet aggregation by inhibiting degranulation of platelets which reduces the release of ADP and thromboxane.

Like other uricosurics, sulfinpyrazone works by competitively inhibiting uric acid reabsorption in the proximal tubule of the kidney.

Contraindications[edit]

Sulfinpyrazone must not be used in persons with renal impairment or a history of uric acid kidney stones.[1]

References[edit]

  1. ^ Underwood M (June 2006). "Diagnosis and management of gout". BMJ. 332 (7553): 1315–9. doi:10.1136/bmj.332.7553.1315. PMC 1473078. PMID 16740561.